Piramal Pharma's Greenhouse Gas Emissions Reduction Commitment Validated by SBTi
Introduction to Piramal Pharma's Sustainability Journey
Piramal Pharma is actively addressing greenhouse gas emissions through its sustainability initiatives. Recently, the Science Based Targets initiative (SBTi) confirmed the company’s ambitious plans to reduce its GHG emissions. This includes a commitment to cut absolute scope 1 and 2 GHG emissions by 42% by FY2030 from a FY2022 baseline.
Details of GHG Emission Reduction Targets
Piramal Pharma’s initiatives extend to scope 3 GHG emissions, aiming for a reduction of 25% across various activities including purchased goods, energy-related operations, and upstream transportation. This strategy underscores the company's dedication to integrate sustainability into its core business practices.
Impact on the Pharmaceutical Industry
With these commitments, Piramal Pharma stands out as the third global pharmaceutical company in India to earn validation from the SBTi. This not only highlights the company’s corporate social responsibility but also sets a precedent for other pharmaceuticals to enhance their environmental practices.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.